Stoke Therapeutics (STOK) Expected to Announce Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK) is expected to be releasing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Stoke Therapeutics to post earnings of ($0.7950) per share and revenue of $4.89 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The company had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. On average, analysts expect Stoke Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Stoke Therapeutics Stock Down 3.9%

Stoke Therapeutics stock opened at $28.86 on Friday. Stoke Therapeutics has a 52-week low of $12.40 and a 52-week high of $40.22. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -10.27 and a beta of 1.17. The company has a fifty day simple moving average of $30.38 and a 200-day simple moving average of $31.99.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. The Goldman Sachs Group assumed coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Weiss Ratings lowered shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Insiders Place Their Bets

In other news, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $30.58, for a total transaction of $54,891.10. Following the transaction, the insider owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at $541,675.70. This represents a 7.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in shares of Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after buying an additional 354 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Stoke Therapeutics during the 4th quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after acquiring an additional 1,149 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Stoke Therapeutics by 12.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock valued at $296,000 after acquiring an additional 1,313 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in Stoke Therapeutics by 2.2% in the fourth quarter. Swiss National Bank now owns 75,700 shares of the company’s stock valued at $2,403,000 after acquiring an additional 1,600 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.